Top Story

Keith C. Ferdinand, MD, highlights recent data on link between CVDs, diabetes drugs

October 30, 2014

BOSTON — At the Cardiometabolic Health Congress, Keith C. Ferdinand, MD, FACC, professor of clinical medicine at Tulane University School of Medicine in New Orleans, outlines recent trial data and FDA updates related to CV and diabetes care.

During a session, Ferdinand discussed a trial that assessed the impact of the GLP-1 agonist dulaglutide on BP and heart rate in a cohort of 755 patients. Ferdinand, who was the principal investigator for the trial, noted a small increase in heart rate with dulaglutide 1.5 mg compared with placebo, but similar results between placebo and dulaglutide 0.75 mg. Patients who received the 1.5 mg dose also exhibited a significant decrease in BP during a 24-hour period. He noted that, while the trial did not assess CV outcomes, results suggest that GLP-1 agonists may aid in BP control, although long-term outcome trials should be performed to determine whether the observed heart rate increase is potentially problematic.

figure Meeting News CoverageVideo

Francesco Rubino, MD: 'Converting' bariatric surgery into a diabetes intervention poses challenges

October 24, 2014
BOSTON — Converting a procedure that has been used for years as a weight-loss intervention into a treatment aimed primarily at diabetes or metabolic disease poses…
figure Meeting News Coverage

Cardiometabolic Health Congress highlights latest research on CVD, diabetes, obesity

October 23, 2014
BOSTON — The latest innovative research in diabetes, hypertension, lipids, obesity and thrombosis was analyzed by experts at the Cardiometabolic Health…
In the Journals

Atherosclerosis risk increased among men with diabetes, low testosterone

October 17, 2014
A greater risk for developing atherosclerosis is found among middle-aged men with low testosterone and type 2 diabetes, according to recent study findings published in…
CME
figure

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »
Meeting News Coverage Video
figure

Keith C. Ferdinand, MD, highlights recent data on link between CVDs, diabetes drugs

October 30, 2014
BOSTON — At the Cardiometabolic Health Congress, Keith C. Ferdinand, MD, FACC, professor of clinical medicine at…
More »
CME
figure

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »

Filter By:

In the Journals

Blood glucose measures offered little benefit for CVD risk prediction

March 25, 2014
Assessment of HbA1c values in the context of CVD risk assessment may provide little incremental benefit for the prediction of CVD risk in people…
In the Journals

Hyperglycemia at hospitalization increased risk for future diabetes in MI patients

March 14, 2014
Approximately one in six patients hospitalized for acute MI have hyperglycemia without known diabetes, and these patients are at a 2.5-fold increased…
In the Journals

Cardiac death, MI remain increased in patients with diabetes treated with DES

March 13, 2014
Among patients treated with drug-eluting stents during the DES era, researchers observed a higher rate of death or MI in those with diabetes compared…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

March 12, 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

Cardiology Today, April 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

March 7, 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

Cardiology Today, April 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
FDA approvals Perspective

FDA approves Myalept for treatment of lipodystrophy

February 25, 2014
The FDA today approved metreleptin, in combination with diet, for the treatment of complications of leptin deficiency in patients with congenital…

FDA to review heart failure risk associated with saxagliptin

February 11, 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…
FDA News

FDA to review heart failure risk associated with saxagliptin

Cardiology Today, April 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…
More Headlines »